비스테로이드성 항염증제(NSAID) 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of non-steroidal anti-inflammatory drugs Market

The global non-steroidal anti-inflammatory drugs market size was valued at USD 24.12 billion in 2025 and is projected to grow from USD 25.76 billion in 2026 to USD 43.68 billion by 2034. The market is supported by the increasing prevalence of chronic pain, arthritis, migraine, inflammation-related disorders, and the continued use of NSAIDs for acute and chronic pain management. North America dominated the market with a 44.03% share in 2025. The U.S. market is also supported by the large patient population suffering from arthritis and chronic pain.

Market Definition and Scope

Non-steroidal anti-inflammatory drugs (NSAIDs) are medicines primarily used to reduce pain, inflammation, and fever. Commonly used drugs include ibuprofen, diclofenac, naproxen, and other prescription and over-the-counter products. They are widely used for conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, migraine, ophthalmic inflammation, and other acute or chronic pain conditions. Growing prescriptions, OTC availability, new product launches, and increasing demand for non-opioid pain management are supporting the market.

Market Trends

Increasing Research on COX-2 Inhibitors is an important trend in the market. Conventional NSAIDs can inhibit both COX-1 and COX-2 enzymes, which may contribute to unwanted gastrointestinal effects. Pharmaceutical companies are therefore investing in selective COX-2 inhibitors and advanced formulations designed to improve pain management while addressing safety concerns.

The growing adoption of online pharmacies is another emerging trend, supported by e-commerce expansion, convenience, wider product availability, and competitive pricing.

Market Dynamics

DRIVER - Rising Prevalence of Chronic Pain

The increasing prevalence of chronic pain and inflammatory diseases is driving demand for NSAIDs. Arthritis, migraine, and other painful conditions require ongoing treatment, while an aging population is contributing to the growing patient pool. Increasing awareness and diagnosis of pain-related conditions are further supporting medication uptake.

DRIVER - Preference for NSAIDs Over Opioids

Concerns surrounding opioid-related adverse events and dependence have encouraged greater interest in non-opioid pain-management options. NSAIDs such as ibuprofen and naproxen are widely recommended for certain mild-to-moderate pain conditions, supporting their continued use.

RESTRAINT - Side Effects of NSAIDs

Gastrointestinal complications, stomach ulcers, stomach pain, dizziness, allergic reactions, and gastrointestinal bleeding can limit NSAID use. Safety concerns are particularly important among patients requiring prolonged treatment, creating challenges for manufacturers and healthcare providers.

Segmentation Analysis

By Disease Indication

The market is segmented into arthritis, migraine, ophthalmic diseases, and others. The arthritis segment is expected to remain dominant because of the rising prevalence of rheumatoid arthritis and osteoarthritis, particularly among older populations. Migraine represents another important application, while ophthalmic NSAIDs are increasingly used following eye surgeries to manage pain and inflammation.

By Route of Administration

The market is divided into oral and parenteral. Oral NSAIDs hold a strong position because of their broad availability, established products, convenience, and extensive prescription and OTC use. Parenteral and topical formulations also provide opportunities, particularly in ophthalmic applications and products such as gels.

By Distribution Channel

The market is categorized into hospital pharmacy, retail pharmacy, and online pharmacy. Hospital pharmacies represent a major distribution channel due to prescriptions and healthcare utilization. Retail pharmacies benefit from OTC availability and demand for products such as ibuprofen and diclofenac. Online pharmacies are expected to gain momentum as consumers increasingly purchase medicines through e-commerce platforms.

Regional Insights

North America dominated the market and recorded a market size of USD 6.86 billion in 2025. The region benefits from the presence of major pharmaceutical companies, high disease prevalence, established healthcare infrastructure, and research activities.

Europe is supported by government healthcare initiatives, reimbursement systems, and the prevalence of migraine and arthritis. Asia Pacific is expected to experience strong growth because of its increasing geriatric population, rising OTC NSAID adoption, and comparatively affordable treatment options. Latin America and the Middle East & Africa are expected to grow with increasing healthcare expenditure and the prevalence of inflammatory diseases.

Competitive Landscape

Leading companies include GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services, Inc., Bayer AG, AstraZeneca, Boehringer Ingelheim International GmbH, Zyla Life Sciences, and Horizon Therapeutics plc. Companies are focusing on product launches, clinical research, portfolio expansion, strategic collaborations, and improved distribution networks.

Key Industry Developments

Perrigo Company plc received FDA approval for an ANDA referencing Voltaren Gel.

Pfizer expanded insurance coverage for Celebrex for adults with rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.

Strides Pharma received U.S. FDA approval for Ibuprofen OTC Capsules, supporting retail availability.

Pfizer also received FDA approval for Eucrisa for the treatment of atopic dermatitis.

Report Coverage

The non-steroidal anti-inflammatory drugs market report covers market size and market value for 2025, 2026, and 2034, disease indications, routes of administration, distribution channels, regional markets, growth drivers, restraints, emerging trends, competitive strategies, product developments, and key industry developments. The analysis also considers disease prevalence, product launches, pipeline activity, collaborations, and mergers and acquisitions affecting the market.

Conclusion

The global non-steroidal anti-inflammatory drugs market is expected to expand from USD 24.12 billion in 2025 to USD 25.76 billion in 2026 and reach USD 43.68 billion by 2034. Rising chronic pain and arthritis prevalence, increasing demand for non-opioid pain-management options, OTC availability, and pharmaceutical innovation will support market expansion. North America remains a major market, while Asia Pacific offers significant growth opportunities due to demographic changes and increasing healthcare adoption. At the same time, gastrointestinal complications and other NSAID-related adverse effects remain important restraints, encouraging manufacturers to pursue safer formulations and selective COX-2 solutions.

By Disease Indication

• Arthritis
• Migraine
• Ophthalmic Diseases
• Others

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Geography

• North America (the U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
• Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)
• Latin America (Brazil, Mexico, and Rest of Latin America)
• Middle East& Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Major Diseases - For Key Countries
• 4.2. Pipeline Analysis
• 4.3. New Product Launches
• 4.4. Key Industry Developments - Mergers, Acquisitions and Partnerships
• 4.5. Key Trends

5. Global Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.2.1. Arthritis
  • 5.2.2. Migraine
  • 5.2.3. Ophthalmic Diseases
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Parenteral
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacy
  • 5.4.2. Retail Pharmacy
  • 5.4.3. Online Pharmacy
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.2.1. Arthritis
  • 6.2.2. Migraine
  • 6.2.3. Ophthalmic Diseases
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacy
  • 6.4.2. Retail Pharmacy
  • 6.4.3. Online Pharmacy
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.2.1. Arthritis
  • 7.2.2. Migraine
  • 7.2.3. Ophthalmic Diseases
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacy
  • 7.4.2. Retail Pharmacy
  • 7.4.3. Online Pharmacy
• 7.5. Market Analysis, Insights and Forecast - By Countries/ Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.2.1. Arthritis
  • 8.2.2. Migraine
  • 8.2.3. Ophthalmic Diseases
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Parenteral
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacy
  • 8.4.2. Retail Pharmacy
  • 8.4.3. Online Pharmacy
• 8.5. Market Analysis, Insights and Forecast - By Countries/ Sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.2.1. Arthritis
  • 9.2.2. Migraine
  • 9.2.3. Ophthalmic Diseases
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Parenteral
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacy
  • 9.4.2. Retail Pharmacy
  • 9.4.3. Online Pharmacy
• 9.5. Market Analysis, Insights and Forecast - By Countries/ Sub regions
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 10.2.1. Arthritis
  • 10.2.2. Migraine
  • 10.2.3. Ophthalmic Diseases
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Parenteral
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacy
  • 10.4.2. Retail Pharmacy
  • 10.4.3. Online Pharmacy
• 10.5. Market Analysis, Insights and Forecast - By Countries/ Sub region
  • 10.5.1. South Africa
  • 10.5.2. GCC
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Company Profiles
  • 11.3.1. GlaxoSmithKline plc
    • 11.3.1.1. Overview,
    • 11.3.1.2. Product & Services,
    • 11.3.1.3. SWOT analysis,
    • 11.3.1.4. Recent developments,
    • 11.3.1.5. strategies,
    • 11.3.1.6. financials (based on availability)
  • 11.3.2. Pfizer Inc.
    • 11.3.2.1. Overview,
    • 11.3.2.2. Product & Services,
    • 11.3.2.3. SWOT analysis,
    • 11.3.2.4. Recent developments,
    • 11.3.2.5. strategies,
    • 11.3.2.6. financials (based on availability)
  • 11.3.3. Johnson & Johnson Services, Inc.
    • 11.3.3.1. Overview,
    • 11.3.3.2. Product & Services,
    • 11.3.3.3. SWOT analysis,
    • 11.3.3.4. Recent developments,
    • 11.3.3.5. strategies,
    • 11.3.3.6. financials (based on availability)
  • 11.3.4. Bayer AG
    • 11.3.4.1. Overview,
    • 11.3.4.2. Product & Services,
    • 11.3.4.3. SWOT analysis,
    • 11.3.4.4. Recent developments,
    • 11.3.4.5. strategies,
    • 11.3.4.6. financials (based on availability)
  • 11.3.5. AstraZeneca
    • 11.3.5.1. Overview,
    • 11.3.5.2. Product & Services,
    • 11.3.5.3. SWOT analysis,
    • 11.3.5.4. Recent developments,
    • 11.3.5.5. strategies,
    • 11.3.5.6. financials (based on availability)
  • 11.3.6. Boehringer Ingelheim International GmbH
    • 11.3.6.1. Overview,
    • 11.3.6.2. Product & Services,
    • 11.3.6.3. SWOT analysis,
    • 11.3.6.4. Recent developments,
    • 11.3.6.5. strategies,
    • 11.3.6.6. financials (based on availability)
  • 11.3.7. Zyla Life Sciences
    • 11.3.7.1. Overview,
    • 11.3.7.2. Product & Services,
    • 11.3.7.3. SWOT analysis,
    • 11.3.7.4. Recent developments,
    • 11.3.7.5. strategies,
    • 11.3.7.6. financials (based on availability)
  • 11.3.8. Horizon Therapeutics plc
    • 11.3.8.1. Overview,
    • 11.3.8.2. Product & Services,
    • 11.3.8.3. SWOT analysis,
    • 11.3.8.4. Recent developments,
    • 11.3.8.5. strategies,
    • 11.3.8.6. financials (based on availability)
  • 11.3.9. Other Prominent Players
    • 11.3.9.1. Overview,
    • 11.3.9.2. Product & Services,
    • 11.3.9.3. SWOT analysis,
    • 11.3.9.4. Recent developments,
    • 11.3.9.5. strategies,
    • 11.3.9.6. financials (based on availability)

12. Strategic Recommendations